What looked like a two-horse hepatitis C race between Gilead Sciences (NASDAQ:GILD) and AbbVie (NYSE:ABBV) has gotten more interesting, with Merck (NYSE:MRK) and Bristol-Myers Squibb (NYSE:BMY) presenting data on their hepatitis C drugs at a scientific meeting earlier this month.

While it's clear Gilead Sciences' Sovaldi combination product will be approved first, closely followed by AbbVie's combo drug, Merck's combination looks just as good and could be on the market in the not-to-distant future if the phase 3 data is as good as the recently presented phase 2 data.

Bristol-Myers Squibb's daclatasvir and asunaprevir are currently under review at the FDA. The pharma is applying for individual approval of the drugs, so daclatasvir -- arguably the more valuable of the two -- could be used in combination with Gilead's Sovaldi, much like Johnson & Johnson's (NYSE:JNJ) Olysio is being used right now.

In the video below, senior biotech specialist Brian Orelli and health-care bureau chief Max Macaluso discus the ever-changing state of the hepatitis C space.

Brian Orelli has no position in any stocks mentioned. Max Macaluso, Ph.D. owns shares of Gilead Sciences. The Motley Fool recommends Gilead Sciences and Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.